Granite Point Capital Management, L.P. Immatics N.V. Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
Shares
2 transactions
Others Institutions Holding IMTX
# of Institutions
85Shares Held
68.8MCall Options Held
507KPut Options Held
170K-
Rtw Investments, LP New York, NY10MShares$125 Million1.69% of portfolio
-
Wellington Management Group LLP Boston, MA8.33MShares$104 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$80.7 Million0.86% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.3MShares$78.9 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY4.58MShares$57.4 Million1.01% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $954M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...